Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

erbB signalling in clinical breast cancer: relationship to endocrine sensitivity

Nicholson, Robert Ian, Gee, Julia Margaret Wendy ORCID: https://orcid.org/0000-0001-6483-2015, Harper, Maureen Elaine, Ellis, I. O., Willsher, P. and Robertson, J. F. R. 1997. erbB signalling in clinical breast cancer: relationship to endocrine sensitivity. Endocrine-Related Cancer 4 (3) , pp. 297-305. 10.1677/erc.0.0040297

Full text not available from this repository.

Abstract

A common phenotypic consequence of the genetic changes that occur in breast cancer is a loss of steroid hormone growth sensitivity, a feature manifested clinically by primary or acquired resistance to antihormones. Although it appears that the absence of steroid receptor machinery determines the failure of oestrogen receptor (ER) negative tumours to respond to endocrine therapies, the erbB signalling pathway seems far from redundant in these tumours and in vivo evidence suggests that elevated epidermal growth factor receptor (EGFR) and c-erbB-2 proteins are fundamental elements in ER negative disease growth control. In contrast, neither diminished ER nor elevated EGFR expression appears to be essential in determining any primary endocrine insensitivity demonstrated by ER positive tumours, although elevated expression of additional erbB pathway components (e.g. transforming growth factor-α, Fos, Myc and c-erbB-2 protein) may be important. However, none of these factors appears to direct endocrine unresponsive, ER positive cell proliferation. Furthermore, it is unlikely that selective outgrowth of endocrine unresponsive, EGFR membrane positive/ER negative cells constitutes a major event in ER positive tumours during their progression towards endocrine resistance.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Pharmacy
Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
Publisher: Society for Endocrinology
ISSN: 1351-0088
Last Modified: 18 Oct 2022 14:19
URI: https://orca.cardiff.ac.uk/id/eprint/17153

Citation Data

Cited 6 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item